These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 21475623)
1. Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study. Formby B; Schmidt F Int J Gen Med; 2011 Feb; 4():159-63. PubMed ID: 21475623 [TBL] [Abstract][Full Text] [Related]
2. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Stephenson K; Neuenschwander PF; Kurdowska AK Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249 [TBL] [Abstract][Full Text] [Related]
4. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516 [TBL] [Abstract][Full Text] [Related]
5. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause. Woodis CB; Ghassemi E; McLendon AN Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556 [TBL] [Abstract][Full Text] [Related]
6. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Burry KA; Patton PE; Hermsmeyer K Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 1):1504-11. PubMed ID: 10368498 [TBL] [Abstract][Full Text] [Related]
7. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524 [TBL] [Abstract][Full Text] [Related]
8. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Antoniou G; Kalogirou D; Karakitsos P; Antoniou D; Kalogirou O; Giannikos L Maturitas; 1997 Mar; 26(2):103-11. PubMed ID: 9089559 [TBL] [Abstract][Full Text] [Related]
9. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Lübbert H; Nauert C Maturitas; 1997 Dec; 28(2):117-25. PubMed ID: 9522319 [TBL] [Abstract][Full Text] [Related]
11. Can climacteric women self-adjust therapeutic estrogen doses using symptoms as markers? Vihtamäki T; Tuimala R Maturitas; 1998 Jan; 28(3):199-203. PubMed ID: 9571594 [TBL] [Abstract][Full Text] [Related]
12. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies. Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047 [TBL] [Abstract][Full Text] [Related]
13. Changes in menopausal symptoms comparing oral estradiol versus transdermal estradiol. Tang R; Xie Z; Ruan X; Zhang Z; Ren M; Wu J; Shu K; Shi H; Xie M; Lv S; Yang X; Chen R; Yu Q Climacteric; 2024 Apr; 27(2):171-177. PubMed ID: 37942806 [TBL] [Abstract][Full Text] [Related]
14. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate. Gambacciani M; Spielmann D; Genazzani AR Gynecol Endocrinol; 2005 Aug; 21(2):65-73. PubMed ID: 16294457 [TBL] [Abstract][Full Text] [Related]
15. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview]. Genazzani AR; Cappagli B; Ciaponi M Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864 [TBL] [Abstract][Full Text] [Related]
16. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751 [TBL] [Abstract][Full Text] [Related]
17. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Somunkiran A; Erel CT; Demirci F; Senturk ML Maturitas; 2007 Jan; 56(1):61-8. PubMed ID: 16831525 [TBL] [Abstract][Full Text] [Related]
18. [Effect of transdermal administration of 17-beta estradiol on the release of growth hormone by growth hormone liberating hormone (GH-RH-1-29) in climacteric women before and after treatment]. Vadillo Buenfil M; García De León LE; Caracas Portilla N; González Bárcena D Ginecol Obstet Mex; 2001 Oct; 69():379-85. PubMed ID: 11816525 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149 [TBL] [Abstract][Full Text] [Related]
20. Estradiol-intranasal: a review of its use in the management of menopause. Dooley M; Spencer CM; Ormrod D Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]